You are here

TGA Internet site archive

The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.

Consultation: Changes to accessing unapproved therapeutic goods through the Authorised Prescriber (AP) and Special Access Schemes (SAS)

15 February 2017

This consultation closed on 29 March 2017.

Invitation to comment

The TGA sought comments from interested parties on the proposed changes to the Special Access Scheme (SAS) and the Authorised Prescriber Scheme.

Consultation documents

How to access a pdf or Word document


Documents released for consultation on Wednesday, 15 February 2017.

Interested parties should respond by close of business Wednesday, 29 March 2017.

Feedback will be released following consideration of submissions. (see 'What will happen').

About the consultation

The TGA is proposing to implement changes that will improve access to unapproved therapeutic goods. The changes will apply to the Special Access Scheme and the Authorised Prescriber Scheme.

The attached consultation document describes the changes proposed and poses questions where feedback was sought.


The MMDR Review made three recommendations to improve access to unapproved therapeutic goods through changes to the SAS and Authorised Prescriber Schemes. These are outlined in recommendations 24, 25 and 26 of the document Review of Medicines and Medical Devices Regulation - Recommendations.

The recommendations made are to decrease duplication of work undertaken and to streamline access to unapproved therapeutic goods which are considered to have an established history of use.


Submissions may address any, or all, of the proposals included in the Changes to Accessing Unapproved Therapeutic Goods through the Authorised Prescriber (AP) and Special Access Schemes (SAS) consultation document.


Any questions relating to submissions should be directed to the Reforms and Operations Section of the Pharmacovigilance and Special Access Branch by email to .

What will happen

All submissions will be placed on this website unless marked confidential or indicated otherwise in the submission form (see Privacy information).

Submissions will be reviewed by the TGA and feedback on submissions will be provided through this website.

Privacy information

  • The TGA collects your personal information in this submission in order to:
    • contact you if the TGA wants to seek clarification of issues raised in your submission or to check whether you consent to certain information that you have provided being made publicly available.
    • help provide context about your submission (e.g. to determine whether you are an individual or a director of a company or representing an interest group).
    • Seek feedback about how the consultation was undertaken.
  • Please do not include personal information about other individuals in the body of your submission. Personal information in this context means information or an opinion about an individual whose identity is apparent, or can reasonably be ascertained, from the information or opinion.
  • More information on consultations and privacy is included in the submission form and on our website.